Skip to main content
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. — Investor Relations & Filings

Ticker · RDHL ISIN · US7574681034 LEI · 52990034U7FZBKRAOE32 US Manufacturing
Open in API
Filings indexed 993 across all filing types
Latest filing 2020-12-14 Regulatory Filings
Country IL Israel
Listing US RDHL

About RedHill Biopharma Ltd.

https://www.redhillbio.com/

RedHill Biopharma is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered, small molecule drugs. The company's primary therapeutic areas of focus are gastrointestinal (GI) diseases, infectious diseases, and oncology. Its key commercial product is Talicia® for the treatment of Helicobacter pylori (H. pylori) infection. RedHill's late-stage clinical development pipeline includes several drug candidates. Among these are Opaganib, a broad-acting, host-directed antiviral and anti-inflammatory agent; RHB-204 for pulmonary nontuberculous mycobacteria (NTM) disease; and RHB-107 (upamostat), an oral serine protease inhibitor. A significant part of its strategy involves developing its assets for pandemic preparedness and as medical countermeasures, emphasizing therapies with viral mutation-resistant properties suitable for stockpiling.

Recent filings

Filing Released Lang Actions
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It contains a press release titled 'RedHill Biopharma Added to NASDAQ Biotechnology Index' and is relatively short (2152 characters). The content is an announcement incorporated by reference and does not contain financial statements or detailed financial data. It is not an annual or interim report, nor a detailed financial or management report. Given the short length and nature of the content (a press release announcement), this fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes Form 6-K filings with press releases.
2020-12-14 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about commercial coverage expansion for a product, Talicia®. The document is short (2210 characters) and primarily serves as a report of a press release rather than a detailed financial report or regulatory filing. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Forms 20-F or 40-F. This document does not contain financial statements, management discussion, or detailed regulatory information. It is not an annual report, earnings release, or any other detailed report type. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-12-07 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about expanding manufacturing capacity for a COVID-19 related product. The document is short (2172 characters) and primarily serves as a regulatory filing to report current events or press releases. It does not contain financial statements, detailed financial analysis, or management discussion. It also does not announce voting results, changes in management, or other specific report types. The document is a typical regulatory announcement filing under the Securities Exchange Act, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous filings that do not fit other categories. Therefore, the correct classification is Regulatory Filings (RNS).
2020-11-25 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, RedHill Biopharma Ltd., with the SEC. It includes a press release about the company's presentation at healthcare conferences. The document length is short (2211 characters) and it primarily announces an event (presentation at conferences) rather than providing detailed financial data or a full report. Form 6-K filings are typically used for current reports by foreign private issuers and often contain announcements or updates rather than comprehensive financial statements. The content does not include financial results, management discussion, or audit information. It is not an annual or interim report, earnings release, or any other detailed financial filing. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-11-23 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by RedHill Biopharma Ltd., which is a report of a foreign private issuer pursuant to the Securities Exchange Act of 1934. It includes a press release about initiating a Phase 3 study, which is typical content for a 6-K filing. The document is short (2184 characters) and primarily serves as a regulatory announcement rather than a full financial report or detailed presentation. It does not contain financial statements or detailed analysis, nor does it announce voting results, management changes, or capital activities. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-11-20 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, RedHill Biopharma Ltd. It contains a press release about a DSMB recommendation related to a clinical study. The document length is 2183 characters, which is relatively short and primarily serves as an announcement rather than a detailed report. It does not contain financial statements or detailed financial analysis. Form 6-K filings are typically used for current reports by foreign private issuers and often include press releases or other material information. Given the short length and nature of the content, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2020-11-19 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.